Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease by Shiffman, Mitchell et al.
Randomised clinical trial: emricasan versus placebo
significantly decreases ALT and caspase 3/7 activation in
subjects with non‐alcoholic fatty liver disease
Mitchell Shiffman1 | Bradley Freilich2 | Raj Vuppalanchi3 | Kymberly Watt4 |
Jean L. Chan5 | Al Spada5 | David T. Hagerty5 | Eugene Schiff6
1Liver Institute of Virginia, Bon Secours
Health System, Richmond and Newport
News, Virginia
2Kansas City Research Institute, Kansas
City, Missouri
3Division of Gastroenterology and
Hepatology, Indiana University School of
Medicine, Indianapolis, Indiana
4Division of Gastroenterology and
Hepatology, Mayo Clinic, Rochester,
Minnesota
5Conatus Pharmaceuticals Inc., San Diego,
California
6Schiff Center for Liver Diseases, University
of Miami Miller School of Medicine, Miami,
Florida
Correspondence
David T. Hagerty, Conatus Pharmaceuticals
Inc., San Diego, CA.
Email: dhagerty@conatuspharma.com
Funding information
Conatus Pharmaceuticals, Inc.
Summary
Background: Lipotoxicity leading to excessive caspase‐mediated apoptosis and
inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan‐caspase
inhibitor that decreased serum ALT and apoptotic and inflammatory markers in sub-
jects with chronic hepatitis.
Aims: To assess whether 28 days of emricasan would reduce elevated levels of
serum ALT, AST, cleaved cytokeratin‐18, full‐length cytokeratin‐18, and caspase 3/7
in subjects with NAFLD and raised aminotransferases.
Methods: Double‐blind, placebo‐controlled, office‐practice study assessed the effi-
cacy, safety, and tolerability of emricasan in subjects with NAFLD and ALT levels
≥1.5 x ULN during screening. Subjects were randomised to emricasan 25 mg twice
daily or matching placebo. Subjects with cirrhosis and other causes for raised amino-
transferases were excluded. The primary endpoint was the change in ALT at day 28
in the emricasan group vs placebo.
Results: 38 subjects were randomised, 19 each to emricasan or placebo. Baseline
disease factors were well balanced except for lower median ALT values in emricasan
subjects. Three subjects randomised to placebo discontinued prior to day 28. ALT
values decreased significantly in emricasan‐treated subjects vs placebo at days 7
(P < 0.0001) and 28 (P = 0.02). cCK18 (day 7), flCK18 (days 7 and 28), and caspase
3/7 (day 7) were also significantly decreased in emricasan‐treated subjects vs pla-
cebo. Emricasan treatment was generally safe and well tolerated.
Conclusions: Emricasan decreased ALT and biomarkers in subjects with NAFLD and
raised aminotransferases after 28 days. These results support the further develop-
ment of emricasan in patients with NAFLD. Trial registration: ClinicalTrials.gov, Iden-
tifier: NCT02077374.
The Handling Editor for this article was Professor Stephen Harrison, and it was accepted
for publication after full peer‐review.
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1 | INTRODUCTION
Non‐alcoholic fatty liver disease (NAFLD) is the most common cause
of chronic liver disease in the US with a prevalence estimated to be
15%‐30%.1–3 Approximately 10%‐20% of patients with NAFLD pro-
gress to non‐alcoholic steatohepatitis (NASH) and 10%‐20% of those
patients will eventually develop cirrhosis.4 Steatohepatitis with fibro-
sis is an important histologic finding that identifies a subgroup of
patients likely to progress to cirrhosis.5,6
Caspases are a family of intracellular cysteine proteases that medi-
ate apoptosis and inflammation through the processing and activation
of pro‐inflammatory cytokines such as IL‐1β, IL‐18, and IL‐33.7 Cellular
injury activates caspases which cleave a number of cell proteins,
including cytokeratin 18 (CK18). Liver aminotransferases associated
with inflammation (ALT, AST) and biomarkers associated with caspase
activation and apoptosis, such as cleaved cytokeratin 18 (cCK18), are
usually elevated in patients with NASH.8,9 The magnitude of apopto-
sis, as measured by levels of cCK18 in serum, correlates with the fibro-
sis stage in NASH patients.10 In addition, therapeutic studies in NASH
patients using pioglitazone and vitamin E revealed that decreases in
ALT and cCK18 were associated with improvements in resolution of
NASH, steatosis, lobular inflammation, hepatocyte ballooning, and
fibrosis stage.11,12 Thus, there is reason to believe that excessive cas-
pase‐mediated apoptosis and inflammation are clinically important dri-
vers of progressive liver disease in NASH and that caspase inhibition
may be able to halt or resolve liver damage in NASH.
Human studies have shown that emricasan lowers ALT and has
anti‐apoptotic and anti‐inflammatory effects in patients with HCV
hepatitis and elevated aminotransferases, as well as in patients with
cirrhosis of different etiologies.13–16 The present study assessed
whether emricasan could lower ALT and biomarkers of hepatocyte
injury, apoptosis, and inflammation in subjects with NAFLD and ele-
vated aminotransferases.
2 | MATERIALS AND METHODS
2.1 | Study oversight
The Sponsor, Conatus Pharmaceuticals Inc, designed the trial. Data were
collected by the investigators in outpatient clinics and analysed by the
Sponsor; the results were reviewed by the Sponsor and the authors. All
authors participated in the writing of the manuscript and approved the
draft that was submitted for publication. The trial was conducted in
accordance with the provisions of the International Conference on Har-
monisation Guidelines for Good Clinical Practice and the Declaration of
Helsinki. The protocol was reviewed and approved by Western IRB or
the Institutional Review Board at each investigational site.
2.2 | Study protocol
This was a placebo‐controlled, multicentre, double‐blind, randomised
trial in subjects with NAFLD/NASH and elevated alanine
aminotransferase values (ALT) conducted in an office practice setting.
Subjects were enrolled between March 2014 and February 2015.
There was a 28‐day double‐blind treatment phase and 28‐day
follow‐up phase. Subjects were required to have two ALT values
≥1.5 times the upper limit of normal (40 IU/L) on at least two occa-
sions during screening. NAFLD was diagnosed by the investigator on
the basis of clinical characteristics and had to be confirmed by either
an imaging test (ultrasound, CT scan, or MRI) or liver biopsy within
6 months of screening. In addition, other causes of chronic liver dis-
ease had to be excluded. Additional exclusions included hepatocellu-
lar carcinoma, inflammatory bowel disease, suspected systemic lupus
erythematosus, or rheumatoid arthritis. Subjects who planned to
make a significant lifestyle change to their diet or exercise regimen
during the study were also to be excluded.
Emricasan (Conatus Pharmaceuticals Inc, San Diego, CA, USA)
25 mg twice daily was studied because that was the lowest dose
that maximally inhibited a panel of four biomarkers (ALT, AST, cas-
pase 3/7, and cCK18 in subjects with hepatitis C [unpublished data]).
2.3 | Blinding and randomisation
The Sponsor, investigational staff, and subjects were blinded to the
treatment assignment throughout the study. Subjects were ran-
domised 1:1 to emricasan or matching placebo using a validated, ver-
ified central randomisation program.
2.4 | Measures of clinical efficacy
The primary efficacy endpoint was the reduction in ALT at day‐28
compared to baseline in subjects treated with emricasan or placebo.
Secondary efficacy endpoints included the change from baseline to
day‐28 in AST, caspase 3/7, cCK18, and flCK18.
Clinical and biomarker measurements were performed by Lab
Connect LLC, Johnson City, TN. CK18 is a major cytoplasmic inter-
mediate filament protein in hepatocytes and epithelial cells that is
cleaved by caspases during apoptosis and cell death. Full‐length
CK18 and caspase‐cleaved CK18 were quantified in sera using
enzyme‐linked immunosorbent assays detecting the M65 epitopes
(M65 EpiDeath, VLVbio, Sundbyberg, Sweden; measures both full‐
length and cleaved CK18, reference range: 63‐311 U/L) and the M30
epitope (M30 Apoptosense, VLVbio, Sundbyberg, Sweden; measures
cleaved CK18 only, reference range: 80‐102 U/L), respectively. Cas-
pase 3/7 activity (Caspase‐Glo 3/7, Promega, Madison, WI, USA; ref-
erence range: 1429‐3908 relative light units) was measured in sera
and detects the executioner caspases 3 and 7.
2.5 | Safety assessments
All adverse events were coded by the Medical Dictionary for Regula-
tory Activities. Treatment‐emergent AEs and serious AEs were sum-
marised by system organ class and preferred term, and stratified by
intensity and relationship to study drug.
Laboratory assessments included serum chemistries, hematology,
urinalysis, and changes in haemoglobin A1c and HOMA‐IR Changes
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from baseline in heart rate, QTc interval, PR interval, and QRS inter-
val were also assessed.
2.6 | Statistical analysis
An estimation approach was applied for the sample size calculation.
With a sample size of 20 in each treatment arm, a two‐sided 95% CI
based on the t‐distribution for the difference of two means would
have an interval that would extend no more than 29.2 U/L from the
observed difference in means with 90% power, assuming that the
common standard deviation for changes from baseline in ALT was
40 U/L.17 If 16 subjects per group completed the study, the interval
would extend no more than ±33.5 U/L.
The full analysis set included all subjects who were randomised
and received at least one dose of study drug. Efficacy analyses were
performed according to the intent to treat principle. Efficacy analy-
ses were conducted on the full analysis set unless noted. Missing
values at day‐28 were imputed using the last observation on‐study.
The safety analysis set included all subjects who took at least
one dose of study drug during the study. Safety analyses were based
on the treatment received. All safety analyses were conducted on
the safety analysis set.
All parameters were analysed descriptively and included the
number of subjects, mean, standard deviation, median, minimum,
maximum, 25th percentile, and 75th percentile. Categorical variables
were presented by frequency counts and percentages. Log transfor-
mations used the natural logarithmic transformation.
The primary study endpoint compared the median change from
baseline in ALT at day 28 in the emricasan group compared to placebo.
Prespecified secondary endpoints for cCK18, flCK18, and caspase 3/7,
compared the difference between treatment groups, as well as the
change from baseline within each treatment group, at days 7 and 28.
The primary treatment comparison at day 28 between the emricasan
and placebo groups used the non‐parametric Wilcoxon‐Mann‐Whitney
test. An analysis of covariance (ANCOVA) on log‐transformed data
adjusting for baseline was performed as a sensitivity analysis. The
median differences between treatment groups were tested using Wil-
coxon‐Mann‐Whitney tests and the corresponding 95% confidence
intervals (CIs) were presented using the Hodges‐Lehmann estimator.
For the natural log‐transformed endpoints, least square mean differ-
ences between treatment groups were obtained by ANCOVA using
treatment group and baseline value as terms in the model, and the cor-
responding 95% CIs were back transformed to provide an estimate of
the ratio (emricasan/placebo).
3 | RESULTS
3.1 | Demographics and baseline disease
characteristics
Baseline demographics and disease characteristics for each treatment
arm were generally balanced (Table 1). More subjects in the
emricasan group were in the age category <44 years (47.4% vs
21.1%), and fewer in the category 45‐64 years (42.1% vs 63.2%),
compared to the placebo group. Weight (241 lbs. vs 228 lbs.) and
BMI (35.0 and 32.6) were slightly higher in the emricasan group
while more subjects were diagnosed with hypertension (47.4% vs
63.2%) and dyslipidaemia (47.4% vs 68.4%) in the placebo group.
Subjects were predominantly male, Caucasian, and under 65 years
old.
3.2 | Disposition
Subject disposition is shown in Figure S1 (CONSORT 2010). Thirty‐
eight subjects were randomised and treated with placebo or emricasan
(19 subjects each). Thirty‐six subjects completed the day 28 visit and
TABLE 1 Demographics and baseline disease characteristics
Placebo (N = 19)
Emricasan
(N = 19)
Gender, n (%)
Male 12 (63.2) 12 (63.2)
Female 7 (36.8) 7 (36.8)
Race, n (%)
Caucasian 17 (89.5) 17 (89.5)
Non‐caucasian 2 (10.5) 2 (10.5)
Age (years), n (%)
<44 4 (21.1) 9 (47.4)
45‐64 12 (63.2) 8 (42.1)
≥65 3 (15.8) 2 (10.5)
Weight (pounds), Mean (SD)
Males 228 (42.8) 241 (44.9)
Females 190 (30.9) 212 (56.5)
BMI (kg/m2), Mean (SD)
Males 32.8 (5.5) 33.8 (5.1)
Females 32.2 (3.0) 37.2 (8.6)
Hypertension, n (%) 12 (63.2) 9 (47.4)
Dyslipidaemiaa 13 (68.4) 9 (47.4)
Diabetes mellitusb 9 (47.4) 8 (42.1)
ALT, Median (range) 92.7 (42.3‐226.7) 65.5 (46.3‐238.9)
AST, Median (range) 44.3 (23.3‐158.8) 43.8 (24.5‐101.1)
cCK18, Median (range) 416.0 (152‐3811) 586.0 (281‐1140)
flCK18, Median (range) 879.0 (431‐5547) 812.0 (317‐1708)
Caspase 3/7, Median
(range)
1356 (300‐2138) 1190 (316‐2478)
HOMA‐IR, Median (range) 5.60 (0.9‐65.5) 5.10 (1.3‐67.9)
HbA1c, Median (range) 6.00 (5.1‐9.8) 5.40 (4.7‐7.5)
aIncludes hypercholesterolaemia, hypertriglyceridaemia, or dyslipidaemia.
bIncludes diabetes mellitus, impaired glucose tolerance, or pre‐diabetes
mellitus.
BMI, body mass index; SD, standard deviation; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; cCK18, cleaved cytokeratin 18;
flCK18, full‐length cytokeratin 18; HOMA‐IR, Homeostatic Model Assess-
ment of Insulin Resistance; HbA1c, hemoglobin A1 c.
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two placebo‐treated subjects prematurely discontinued from the study
prior to the day 28 visit. The reasons for discontinuation were “viola-
tion of inclusion or exclusion criteria” (one subject started metformin
treatment on day 2) and “other” (increased work‐related travel, one
subject). The first subject entered the study in March 2014 and the
last subject completed the study in February 2015.
3.3 | Changes in ALT
The primary study endpoint was the median change from baseline in
ALT at day 28 in the emricasan group vs placebo. Median ALT val-
ues at baseline and on study days 7, 28, and 56 (off treatment) are
shown in Figure 1A. Median day 7 ALT values decreased −8.7 IU/L
in the placebo group and −36.7 IU/L in the emricasan group (95% CI
[−51.8, −22.8]; P < 0.0001 compared to placebo). At day 28, median
ALT values decreased −9.4 IU/L in the placebo group and −25.8 IU/L
in the emricasan group (95% CI [−30.7, −2.5]; P = 0.02 compared to
placebo). ALT values returned towards baseline by day 56 without
evidence of overshoot. There were two subjects in the emricasan
group who were non‐compliant, one of whom missed ~25% of doses
and another who missed >20% of doses and had undetectable levels
of both parent drug and long‐lasting metabolites at day 28. When
those two subjects were excluded, ALT values on day 7 and 28 were
more similar (32.3 and 37.5 U/L, respectively).
A sensitivity analysis (Wilcoxon‐Mann‐Whitney test, per‐protocol
population) confirmed the primary analysis and showed a statistically
significant difference in favour of emricasan (P = 0.017) at day 28.
An ANCOVA sensitivity analysis on log‐transformed ALT, using the
full analysis set, also showed a statistically significant reduction in
ALT in the emricasan group vs placebo (ratio of 0.6524; P = 0.0006)
at day 28.
Individual subject changes in ALT were plotted. This analysis
excluded the two non‐compliant subjects in the emricasan group. All
other subjects, including eight subjects with borderline compliance
who missed 10%‐20% of doses, were included in the analysis. Every
subject treated with emricasan had a decrease in ALT at days 7 and
28 (Figure 2A). At day 7, 11/17 (64.7%) of subjects treated with
emricasan achieved an ALT value within the normal range (upper
limit of lab normal: 40 IU/L). At day 28, 9/17 (52.9%) of emricasan‐
treated subjects had ALT values that remained within the normal
range and two additional subjects had values of 40.3 and 41.1 IU/L.
Responses at the day 28 visit remained less than baseline in all sub-
jects, although some subjects had an increase in ALT values com-
pared to day 7. Changes in ALT for individual subjects treated with
placebo are shown in Figure 2B. In the placebo‐treated subjects, 2/
19 subjects (10.5%) at day 7 had ALT values ≤40 IU/L. At day 28, 3/
19 placebo‐treated subjects (15.8) had ALT values <40 IU/L.
3.4 | Changes in AST
Median AST values at baseline were relatively lower compared to
ALT (44.3 and 43.8 in the placebo and emricasan subjects, respec-
tively) and are shown on study days 7, 28, and 56 (off treatment) in
Figure 1B. Median day 7 AST values increased +1.5 IU/L in the pla-
cebo group and decreased −20.1 IU/L in the emricasan group (95%
CI [−36.65, −15.4]; P = 0.0002 compared to placebo). At day 28,
median AST values decreased −5.2 IU/L in the placebo group and
−6.7 IU/L in the emricasan group (95% CI [−14.5, 11.2]; P = 0.8724).
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AST values returned towards baseline by day 56 without evidence
of overshoot.
Individual subject responses were also examined for AST. This
analysis also excluded the two non‐compliant subjects. Every subject
treated with emricasan had a lower AST value at day 7, and all but one
subject normalised their AST value at day 7 (Figure 2C). There was
more variability in the AST response at day 28 in the emricasan‐trea-
ted subjects when compared to ALT. Sixteen out of seventeen emric-
asan‐treated subjects (94.1%) had an AST value ≤ULN at day 7, while
9/18 (50%) had AST values ≤ULN at day 28. In the placebo‐treated
subjects (Figure 2D), 3/19 (15.8%) and 6/19 (31.6%) of placebo‐treated
subjects had an AST value ≤ULN at days 7 and 28, respectively.
3.5 | Changes in biomarkers of excessive caspase
activation
The prespecified analysis plan stated that cCK18, flCK18, and cas-
pase 3/7 would be analysed two ways: as the change from
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baseline within each treatment group and the difference between
treatment groups at days 7 and 28. All three biomarkers of exces-
sive caspase activation were elevated at baseline and showed sig-
nificant decreases with emricasan treatment while placebo
treatment showed no significant change in any of the biomarkers.
Figure 3 shows the median values of cCK18 (Figure 3A), flCK18
(Figure 3B), and caspase 3/7 (Figure 3C) at baseline and on days
7, 28, and 56.
Baseline values of cCK18 were elevated compared to values pre-
viously observed in three studies in which healthy volunteers were
treated with emricasan (median values in each study of 240, 161.5
and 223.5 U/L, unpublished data). Subjects treated with placebo had
a median baseline cCK18 value of 416.0 U/L which increased by
+4.5 U/L at day 7 (P = 0.8401). Subjects treated with emricasan had
a median baseline cCK18 value of 586.0 U/L which decreased by
−284.0 U/L at day 7 (P < 0.0001 compared to baseline, P = 0.0015
cCK18
Caspase 3/7
flCK18
EMR
Pbo
EMR
Pbo
EMR
Pbo
P = 0.1149
P = 0.0471
P = 0.0023
*
*
P = 0.0015
P = 0.0124
*
P = 0.1365
*
Visit day
7Baseline
0 0
250
500
750
1000
1250
1500
1750
2000
2250
2500
2750
0
250
500
750
1000
1250
1500
1750
2000
2250
250
500
750
cC
K1
8 
(U
/L)
Ca
sp
as
e 
3/
7 
(R
LU
)
flC
K1
8 
(U
/L)
1000
1250
1500
1750
28 56
Visit day
7Baseline 28 56
Visit day
7Baseline 28 56
(A)
(C)
(B)
F IGURE 3 Baseline and on‐treatment (days 7 and 28) values of cCK18 (mean, panel A), flCK18 (mean, panel B), and caspase‐3/7 (median,
panel C). On‐treatment values statistically different (P < 0.05) from placebo are indicated and the error bars are the standard deviation (SD)
values
SHIFFMAN ET AL. | 69
vs placebo). At day 28, placebo‐treated subjects had an increased
cCK18 value relative to baseline (+14.0; P = 0.7983) and emricasan‐
treated subjects had decreased cCK18 values relative to baseline
(−183.0 U/L; P = 0.0033) but the emricasan group was not signifi-
cantly different from placebo (P = 0.1149).
Similar results were observed for flCK18 (Figure 3B). Baseline
values of flCK18 were elevated compared to values previously
observed in three studies in which healthy volunteers were treated
with emricasan (median values in each study of 334, 284, and
427.5 U/L, unpublished data). Subjects treated with placebo had a
median baseline flCK18 value of 879.0 U/L which increased by
+32.5 U/L at day 7 (P = 0.9661). Subjects treated with emricasan
had a median baseline flCK18 value of 812.0 U/L which decreased
by −534.5 U/L at day 7 (P < 0.0001 compared to baseline,
P = 0.0023 vs placebo). At day 28, placebo‐treated subjects had an
increased flCK18 value relative to baseline (+4.0 U/L, P = 1.0000)
and emricasan‐treated subjects had decreased flCK18 values
(−296.0 U/L). The day 28 value in the emricasan‐treated subjects
was significantly different from baseline (P = 0.0006) and signifi-
cantly different from placebo (P = 0.0471).
The results for caspase 3/7 activity are shown in Figure 3C.
Baseline caspase 3/7 values were at the upper range of values previ-
ously observed in three studies in which healthy volunteers were
treated with emricasan (median values in each study of 919.5, 963.5,
and 1290 RLU, unpublished data). Subjects treated with placebo had
a median baseline caspase 3/7 value of 1356 RLU which decreased
by −52.5 RLU at day 7 (P = 0.2247). Subjects treated with emricasan
had a median baseline caspase value of 1190 RLU which decreased
by −228.5 RLU at day 7 (P < 0.0001 compared to baseline,
P = 0.0124 vs placebo). At day 28, placebo‐treated subjects had an
increased caspase 3/7 value relative to baseline (+68.0 RLU,
P = 0.7680) and emricasan‐treated subjects had decreased caspase
3/7 values (−287.0 RLU). The day 28 value in the emricasan‐treated
subjects was significantly different from baseline (P = 0.0108) but
not significantly different from placebo (95% CI [−590, 63];
P = 0.1365).
Values for all three biomarkers returned towards baseline values
after emricasan treatment was stopped for 28 days (day 56 visit).
3.6 | Potential effect of weight change on efficacy
measures
Any subject who planned to make a significant lifestyle change to
their diet and exercise regimens during the study was to be
excluded. Nevertheless, three subjects (one randomised to placebo,
two randomised to emricasan) had a weight change of greater than
five pounds (−9 lbs. in the placebo subject, and −18 and +14 lbs. in
the emricasan subjects) between screening and day 28. To assess
the potential effect of weight change on the study conclusions,
these three subjects were excluded from analysis and the changes in
ALT, AST, cCK18, flCK18, and caspase 3/7 between the emricasan
and placebo groups at day 28 were again compared. The decreases
in ALT and flCK18 at day 28 remained significant in the subjects
treated with emricasan compared to placebo. The non‐significant dif-
ference between the emricasan and placebo groups for cCK18 at
day 28 became significant (P = 0.0477) when those three subjects
were excluded. Excluding those three subjects had essentially no
effect on the p values for AST and caspase 3/7 at day 28. Overall,
change in weight did not have a major confounding effect upon the
overall study results.
3.7 | Changes in other chemistry values
There were no significant differences between treatment groups in
serum values of alkaline phosphatase, gamma glutamyl transpepti-
dase, amylase, or lactate dehydrogenase at days 7 or 28. There were
no significant differences between treatment groups in lipid parame-
ters, including total cholesterol, low‐density lipoprotein cholesterol,
high‐density lipoprotein cholesterol, or triglyceride values at day 28
(not measured on day 7). There were no significant differences
between treatment groups at day 28 in measures of glucose toler-
ance or control, including insulin levels, haemoglobin A1c, serum glu-
cose, and HOMA‐IR (not measured on day 7). Circulating
inflammatory markers were not measured.
3.8 | Analysis of adverse events
Emricasan treatment was generally well tolerated. Table 2 shows an
overview of AEs. The number of AEs reported per group, number of
subjects reporting any AE, and number of subjects with serious,
moderate, and severe AEs was similar between the placebo and
emricasan groups (Table 2). Most AEs were mild. Two subjects in
each group reported moderate AEs. No severe AEs were reported.
Most AEs were reported by only one subject. The only events
reported by two subjects were frequent bowel movements, chest
pain, and headache in the emricasan arm, and the urinary tract infec-
tion in the placebo arm (Table 3). One AE (dry mouth) in a placebo
subject was considered by the investigator as possibly related to
blinded treatment. No deaths were reported during the study.
One subject in each group reported a serious AE. Neither was
felt to be related to study medication (Table 2). A placebo‐treated
TABLE 2 Overview of adverse events (AEs)
Placebo
(N = 19)
Emricasan
(N = 19)
Number of AEs 20 23
Number (%) of serious AEs 1a (5.3) 1b (5.3)
Number (%) of subjects with any AE 8 (42.1) 10 (52.6)
Number (%) of subjects with related AE 1 (5.3) –
Number (%) of subjects with moderate AE 2 (10.5) 2 (10.5)
Number (%) of subjects with severe AE 0 0
Number (%) of subjects with AE leading
to interruption of study medication
– 1 (5.3)
aGastrointestinal haemorrhage.
bCellulitis.
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subject reported a GI haemorrhage and an emricasan‐treated mor-
bidly obese diabetic subject had lower extremity cellulitis.
There were no adverse effects of emricasan upon any laboratory
tests, serum lipids, glucose, vital signs, or EKG parameters.
4 | DISCUSSION
This proof‐of‐concept study provides evidence that emricasan lowers
ALT and inhibits excessive caspase activation in subjects with NASH
and elevated aminotransferases. Both total levels of cytokeratin‐18
(flCK18) as well as cleaved cytokeratin‐18 (cCK18) were reduced by
emricasan. Circulating levels of the executioner caspases −3 and −7
were also reduced. Of note, cCK18, flCK18, and caspase‐3/7 activity
were reduced towards, but not below, median values observed in
healthy volunteer studies. This is consistent with previously pub-
lished data from healthy volunteers treated with a single 25 mg dose
or 25 mg twice‐daily of emricasan for 10 days where no effect on
cCK18, flCK18, or caspase‐3/7 was observed.18 Thus, there appears
to be a basal level of normal apoptosis that is not affected by emric-
asan, perhaps since OATP1B1 and 1B3 expression is primarily lim-
ited to hepatocytes and enterocytes,19 and emricasan exhibits
relatively poor passive diffusion across cell membranes (unpublished
data).
One important observation in this study is that serum ALT levels
decreased to below 40 IU/L in approximately 65% of emricasan‐trea-
ted patients by the day 7 visit and the response was maintained in
most subjects through the final day 28 visit. Normalisation of ALT
values in NASH patients has been associated with improvement in
liver histology. The 96‐week PIVENS study20 that compared vitamin
E, which is believed to mitigate hepatocyte oxidative stress, and
pioglitazone to placebo showed that both vitamin E and pioglitazone
reduced ALT levels, steatosis, and lobular inflammation. A subse-
quent post‐hoc analysis of the PIVENS data showed that if ALT
levels were elevated at baseline, a decrease of at least 30%‐40 IU/L
or less predicted improvement in most histologic liver disease mea-
sures.21 Other studies have also shown that decreases in ALT are
usually associated with improvement in histological activity in NASH
patients.22 Thus, proof‐of‐concept for ALT reduction with emricasan
in setting of excessive caspase activation warrants further investiga-
tion.
Caspase inhibition is a novel approach to treating NASH that is
believed to modulate the hepatocyte response to toxic levels of
lipids. Excessive hepatocyte apoptosis has been repeatedly observed
in patients with NASH9,10 and lipotoxicity is an important mecha-
nism of hepatocyte injury that leads to caspase activation, apoptosis,
inflammation, and fibrosis in NASH.23 Mice genetically deficient in
either caspase‐1, −3, or −8 are resistant to diet‐induced NASH.24,25
Caspase activation following lipotoxic and other forms of liver injury
is one of the important pathways that results in hepatocyte apopto-
sis, inflammation, and fibrosis.23,26
Caspase inhibition with emricasan was previously found to
decrease apoptosis and return elevated liver aminotransferases
towards normal in patients with hepatitis C infection.13,14 Two
recent studies in patients with cirrhosis of different etiologies (in-
cluding NAFLD, hepatitis C, and alcohol use) also showed small
decreases in ALT and AST after treatment with emricasan for
28 days or up to 6 months. In the 28 day uncontrolled cirrhosis
study, all subjects were compensated and the decrease in ALT rela-
tive to baseline was statistically significant.15 In the 6‐month cirrho-
sis study (placebo‐controlled for 3 months), nearly all subjects were
decompensated, mean baseline ALT values were well‐within the nor-
mal range, and the observed treatment effect on ALT vs placebo at
3 months was small and not significant.16 The present study extends
those findings to patients with non‐cirrhotic NAFLD by showing that
pan‐caspase inhibition with emricasan improved elevated amino-
transferases and decreased markers of excessive caspase activation
over 28 days of treatment. Serum ALT levels were elevated at
TABLE 3 Most frequent adverse events (AEs) by system organ
class and preferred term
System organ class
Preferred term
Placebo
(N = 19)
Emricasan
(N = 19)
Blood and lymphatic system 1 (5.3) –
Endocrine – 1 (5.3)
Hyperthyroidism
Gastrointestinal 5 (26.3) 3 (15/8)
Frequent bowel movements 2 (10.5)
General disorders and administration
site conditions
1 (5.3) 3 (15.8)
Chest pain – 2 (10.5)
Immune system – 1 (5.3)
Hypersensitivity
Infections and infestations 2 (10.5) 4 (21.1)
Bronchitis 1 (5.3) –
Cellulitis – 1 (5.3)
Pharyngitis streptococcal – 1 (5.3)
Urinary tract infection 2 (10.5) 1 (5.3)
Viral upper respiratory tract infection – 1 (5.3)
Musculoskeletal and connective tissue
disorder
1 (5.3) 1 (5.3)
Groin pain 1 (5.3)
Pain in extremity 1 (5.3)
Nervous system – 3 (15.8)
Headache – 2 (10.5)
Renal and urinary disorders – 1 (5.3)
Renal failure acute
Respiratory, thoracic, and mediastinal
disorders
2 (10.5) –
Cough
Nasal congestion
Skin and subcutaneous tissue disorders 1 (5.3) –
Psoriasis
Total 8 (42.1) 10 (52.6)
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baseline and decreased to below 40 IU/L in approximately 65% of
emricasan‐treated patients by the day 7 visit and the response was
maintained in most subjects through the final day 28 visit. Improve-
ment in other biomarkers associated with liver inflammation (AST)
and excessive caspase activity (caspase 3/7 activity and cCK18 and
flCK18 levels) was also observed. In this study, baseline levels of
cCK18 and flCK18 were 2‐ to 3‐fold higher than those observed in
the emricasan cirrhosis studies,15,16 and decreases in the emricasan‐
treated subjects were clear. Conversely, baseline levels of caspase 3/
7 were 2‐ to 3‐fold higher in the cirrhosis studies compared to this
study, and decreases in caspase 3/7 in those studies were more
obvious with emricasan treatment. In general, it is easier to observe
decreases in a biomarker that is elevated compared to when the bio-
marker is near‐normal. It is possible that higher levels of the execu-
tioner caspases 3/7 observed in the cirrhosis studies resulted in
lower levels of cCK18 and flCK8 due to a lower hepatocyte cell
mass (and CK18 substrate) in cirrhosis subjects. Conversely, the
lower levels of caspases 3/7 observed in this study resulted in higher
levels of cCK18 and flCK18, potentially due to a greater hepatocyte
mass (and CK18 substrate). Complicating interpretation of these
observations in subjects with normal vs impaired liver function, is
that production and clearance rates influence steady‐state serum
levels, and those rates for cCK18, flCK18, and caspase 3/7 are
poorly understood in both groups of subjects.
Dietary modifications, exercise, and bariatric surgery with resul-
tant weight loss have all been shown in some studies to improve
NAFLD or NASH.27,28 However, diet and exercise alone are fre-
quently not successful and surgery is not always an option. Treating
insulin resistance with insulin‐sensitizing therapies or thiazolidine-
diones (eg, pioglitazone) may improve insulin sensitivity, hepatic fat
content, and resolve NASH, but may not improve fibrosis.18–21
Vitamin E is an anti‐oxidant that is postulated to improve the
hepatocellular response to oxidative stress. Pilot studies showed that
vitamin E treatment could lower elevated aminotransferase
levels.29,30 The larger PIVENS study that compared vitamin E and
pioglitazone to placebo following 96 weeks of treatment20 showed
that while both vitamin E and pioglitazone reduced ALT levels,
steatosis, and lobular inflammation, neither showed a statistically sig-
nificant effect upon fibrosis (P = 0.24 and 0.12, respectively). A sub-
sequent post‐hoc analysis of the PIVENS data showed that if ALT
levels were elevated at baseline, a decrease of at least 30% to
40 IU/L or less predicted improvement in most histologic liver dis-
ease measures but not fibrosis.21 Other studies have also shown that
decreases in ALT are usually associated with improvement in histo-
logical activity in NASH patients.22
Emricasan treatment was generally safe and well‐tolerated in this
28 day study. Future studies with larger numbers of subjects and
longer duration are needed to better define the safety and efficacy
profile of emricasan in patients with NASH fibrosis. Additional safety
information is available from studies that were recently completed in
which patients with cirrhosis were treated for 28 days15 and up to
6 months.16 Twenty‐three patients were treated with emricasan in
the 28 day cirrhosis study. Only one patient reported a serious
adverse event and the most common adverse events (≥5% of
patients) were fatigue, headache, edema, dehydration, diarrhea, con-
stipation, and nausea. In the 6 month cirrhosis study (placebo‐con-
trolled for 3 months), serious adverse events and adverse events
leading to discontinuation were balanced between treatment groups.
Adverse events were also generally balanced between treatment
groups with the most common adverse events (≥5% of patients)
being headache, nausea, hepatic encephalopathy, vomiting, fatigue,
abdominal pain, arthralgia, and urinary tract infection.
While the study met the primary endpoint for ALT reduction at
day 28, it was not prospectively sized to detect treatment differ-
ences for other biomarkers such as cCK18, flCK18, or caspase 3/7.
While statistically significant differences were noted at day 7 (cCK18
and flCK18) and day 28 (flCK18 and caspase 3/7) there was no
adjustment of p values for multiplicity and these effects will need
confirmation in future studies. In addition, while reduction in ALT
has been a reliable predictor for improvement in NASH histology,
future studies are needed to assess whether emricasan will improve
liver histology in NASH.
ACKNOWLEDGEMENTS
Declaration of personal interests: Mitchell Shiffman has served on the
advisory boards of Abbvie, Bayer, Bristol Myers‐Squibb, Dova, Gilead,
Intercept, Merck, Salix, and Shionogi; has been a speaker for Abbvie,
Bayer, Bristol Myers‐Squibb, Daiichi Sankyo, Dova, Enanta, Gilead,
Intercept, Merck, Salix, and Shionogi; is a consultant for Optum Rx;
and has received grant support from Abbvie, Bristol Myers‐Squibb,
CymaBay, Conatus, Enanta, Exalenz, Galectin, Genfit, Gilead, Genky-
otex, Intercept, Immuron, Merck, NGMBio and Novartis. Shire Kym-
berly Watt has received grant support from Conatus, Gilead and
Intercept. Raj Vuppalanchi has received grant support from Bristol
Myers‐Squibb, Conatus, Gilead Sciences, Intercept and NGM Bio.
Bradley Freilich has been a speaker for Gilead and Intercept and has
received grant support from Abbvie, Advanced Accelerator Applica-
tions, Array Biopharma, Boston Mbiomedical, Conatus, Effector Phar-
maceuticals, EMD Serono, Enanta Pharmaceuticals, Genfit, Gilead,
Immuron Ltd, Intercept, NGM Bio, Novartis, Roche, Shire, SillaJen Inc,
Synteract and Theravance Biopharma. Eugene Schiff has served on
the advisory boards of Bristol‐Myers Squibb, Gilead and Merck; is a
consultant for Dova and Arbutus Biopharma; and has received grant
support from Beckman, Bristol‐Myers Squibb, Conatus, Discovery Life
Sciences, Genfit, Gilead, Intercept, Novo Nordisk, Orasure Technolo-
gies, Ortho Diagnostics, Pfizer, Prometheus Lab, Roche Diagnostics,
Shire, Siemens, Target Pharma Solutions, Tobira and Wiley. J. Chan, A.
Spada, and D. Hagerty are employees of Conatus Pharmaceuticals Inc.
A. Spada is a stockholder of Conatus Pharmaceuticals Inc. None of the
authors own patents related to emricasan.
Declaration of funding interests: This study and the preparation of
this paper was funded in full by Conatus Pharmaceuticals Inc. The
authors who are employees of Conatus Pharmaceuticals Inc. were
involved in the data analysis and writing of the manuscript. There
was no additional writing support.
72 | SHIFFMAN ET AL.
AUTHORSHIP
Guarantor of the article: David T. Hagerty.
Author contributions: All authors contributed to the acquisition,
analysis, and interpretation of the data; revised the manuscript criti-
cally for important intellectual content; approved the final manu-
script, including the authorship list; and agreed to be accountable for
the overall accuracy or integrity of the study results.
ORCID
David T. Hagerty http://orcid.org/0000-0002-1837-3935
REFERENCES
1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epi-
demiology and natural history of non‐alcoholic fatty liver disease and
non‐alcoholic steatohepatitis in adults. Aliment Pharmacol Ther.
2011;34:274‐285.
2. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic
steatosis in an urban population in the United States: impact of eth-
nicity. Hepatology. 2004;40:1387‐1395.
3. Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty
liver disease with advanced fibrosis in the US: a cross‐sectional anal-
ysis of 2011–2014 National Health and Nutrition Examination Sur-
vey. Aliment Pharmacol Ther. 2017;46:974‐980.
4. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD
and NASH. Clin Liver Dis. 2007;11:1‐16.
5. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for
nonalcoholic steatohepatitis: interprotocol agreement and ability to
predict liver‐related mortality. Hepatology. 2011;53:1874‐1882.
6. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest
predictor for disease‐specific mortality in NAFLD after up to 33
years of follow‐up. Hepatology. 2015;61:1547‐1554.
7. Afonina IS, Muller C, Martin SJ, et al. Proteolytic processing of inter-
leukin‐1 family cytokines: variations on a common theme. Immunity.
2015;42:991‐1004.
8. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver
cell apoptosis as a novel biomarker of disease severity in nonalco-
holic fatty liver disease. Hepatology. 2006;44:27‐33.
9. Yilmaz Y, Dolar E, Ulukaya E, et al. Elevated serum levels of caspase‐
cleaved cytokeratin 18 (CK18‐Asp396) in patients with nonalcoholic
steatohepatitis and chronic hepatitis C.Med Sci Monit. 2009;15:189‐193.
10. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and
fas expression are prominent features of human nonalcoholic steato-
hepatitis. Gastroenterology. 2003;125:437‐443.
11. Jain AK, Deppe RB, Yates KP, et al. Serum keratin fragment 18
(CK18) levels significantly predict changes in liver histology in chil-
dren and adolescents with nonalcoholic fatty liver disease (NAFLD):
Results from the TONIC trial. Hepatology. 2013;58:264A.
12. Vuppalanchi R, Deppe RB, Yates KP, et al. Changes in serum cytok-
eratin 18 levels significantly predict changes in liver histology in
adults with nonalcoholic steatohepatitis: results from the Pivens trial.
Gastroenterology. 2013;144:S‐951.
13. Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN‐6556, an anti-
apoptotic caspase inhibitor, may lower aminotransferase activity in
patients with chronic hepatitis C. Hepatology. 2007;46:324‐329.
14. Shiffman ML, Pockros P, McHutchison JG, et al. Clinical trial: the
efficacy and safety of oral PF‐03491390, a pancaspase inhibitor ‐ a
randomized placebo‐controlled study in patients with chronic hepati-
tis C. Aliment Pharmacol Ther. 2010;31:969‐978.
15. Garcia‐Tsao G, FuchsM, ShiffmanM, et al. Emricasan (IDN‐6556) lowers
portal pressure in patients with compensated cirrhosis and severe portal
hypertension.Hepatology. 2018. https://doi.org/10.1002/hep.30199
16. Frenette CT, Morelli G, Shiffman ML, et al. Emricasan improves liver
function in patients with cirrhosis and high model for end‐stage liver
disease scores compared with placebo. Clin Gastroenterol Hepatol.
2018. pii: S1542-3565(18)30622‐0. https://doi.org/10.1016/j.cgh.
2018.06.012 [Epub ahead of print.]
17. Ratziu V, Sheikh MY, Sanyal AJ, et al. A phase 2, randomized, dou-
ble‐blind, placebo‐controlled study of GS‐9450 in subjects with non-
alcoholic steatohepatitis. Hepatology. 2012;55:419‐428.
18. Spada A, Contreras P, Huyghe M, et al. Physiologically normal levels
of apoptosis in healthy volunteers are not reduced by the pan cas-
pase inhibitor emricasan. Hepatol. 2013;58(Suppl 1):949A.
19. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacoki-
netics. Br J Pharmacol. 2009;158:693‐705.
20. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E,
or placebo for nonalcoholic steatohepatitis. N Engl J Med.
2010;362:1675‐1685.
21. Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in
serum alanine aminotransferase levels in patients with non‐alcoholic
steatohepatitis. Aliment Pharmacol Ther. 2013;38:134‐143.
22. Vilar‐Gomez E, Calzadilla‐Bertot L, Friedman SL, et al. Serum
biomarkers can predict a change in liver fibrosis 1 year after lifestyle
intervention for biopsy‐proven NASH. Liver Int. 2017;37:1887‐1896.
23. Hirsova P, Gores GJ. Death receptor‐mediated cell death and proin-
flammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gas-
troenterol Hepatol. 2015;1:17‐27.
24. Hatting M, Zhao G, Schumacher F, et al. Hepatocyte caspase‐8 is an
essential modulator of steatohepatitis in rodents. Hepatology.
2013;57:2189‐2201.
25. Thapaliya S, Wree A, Povero D, et al. Caspase 3 inactivation protects
against hepatic cell death and ameliorates fibrogenesis in a diet‐in-
duced NASH model. Dig Dis Sci. 2014;59:1197‐1206.
26. Yoon JH, Gores GJ. Death receptor‐mediated apoptosis and the
liver. J Hepatol. 2002;37:400‐410.
27. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver dis-
ease: improvement in liver histological analysis with weight loss.
Hepatology. 2004;39:1647‐1654.
28. Bower G, Toma T, Harling L, et al. Bariatric surgery and non‐alco-
holic fatty liver disease: a systematic review of liver biochemistry
and histology. Obes Surg. 2015;25:2280‐2289.
29. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in
children: a pilot study. J Pediatr. 2000;136:734‐738.
30. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E
versus vitamin E and pioglitazone for the treatment of nonalcoholic
steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107‐1115.
SUPPORTING INFORMATION
Additional supporting information will be found online in the
Supporting Information section at the end of the article.
How to cite this article: Shiffman M, Freilich B, Vuppalanchi
R, et al. Randomised clinical trial: emricasan versus placebo
significantly decreases ALT and caspase 3/7 activation in
subjects with non‐alcoholic fatty liver disease. Aliment
Pharmacol Ther. 2019;49:64–73. https://doi.org/10.1111/
apt.15030
SHIFFMAN ET AL. | 73
